|
全民健康保險藥品給付規定 / 健保碼及健保價 |
|
See related Aloxi inj[嘔立舒 注射劑] information |
|
|
|
製造商 |
Pierre-Fabre |
|
代理/經銷商 |
Pierre-Fabre |
|
成份 |
Palonosetron |
|
適應症 |
Prevention of acute &/or delayed nausea & vomiting associated with initial & repeat courses of moderately or highly emetogenic cancer chemotherapy. |
|
用量 |
Adult Single 0.25 mg IV dose administered over 30 seconds. To be administered 30 mins before the start of chemotherapy. |
|
美國食品藥物管理局之懷孕等級 |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
注意事項 |
Hypersensitivity to other 5-HT3 receptor antagonists. Prolongation of cardiac conduction intervals particularly QTc in patients with hypokalemia or hypomagnesemia, congenital QT syndrome; patients on diuretics with potential for inducing electrolyte abnormalities; or on antiarrhythmics or other drugs which lead to QT prolongation & cumulative high dose anthracycline therapy. Patients <18 years, pregnancy, lactation. |
|
不良反應 |
Headache, constipation, diarrhea, dizziness, fatigue, abdominal pain, insomnia.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Aloxi 注射劑 |
|
Aloxi 0.05 mg/1 mL x 5 mL |
|
|
|
Manufacturer: |
Pierre-Fabre |
|
Distributor: |
Pierre-Fabre
|
|
|
|
